Attenuation of echinocandin activity at elevated concentrations: A review of the paradoxical effect

Current Opinion in Infectious Diseases

Volumn 20, Issue 6, 2007, Pages 574-578

  Wiederhold, Nathan P ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Anidulafungin; Aspergillus; Candida; Caspofungin; Echinocandins; Micafungin; Paradoxical effect

Indexed keywords

ANIDULAFUNGIN; CALCINEURIN; CANDIDAS; CASPOFUNGIN; CHITIN; CILOFUNGIN; ECHINOCANDIN; MICAFUNGIN; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CONCENTRATION RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MYCOSIS; NONHUMAN; REVIEW; SACCHAROMYCES CEREVISIAE;

ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHINOCANDINS; HUMANS; MYCOSES;

EID: 35848946331     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3282f1be7f     Document Type: Review

References (49)

1. Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38:1480-1489.
2. Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 2003; 12:1313-1333.
3. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-2029.
4. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519-1527.
5. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472-2482.
6. Andes D, Marchillo K, Lowther J, et al. In vivo pharmacodynamics of HMR 3270 a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47:1187-1192.
7. Gumbo T, Drusano GL, Liu W, et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007; 51:968-974.
8. Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190:1464-1471.
9. Eagle H, Musselman AD. The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 1948; 88:99-131.
10. Hall GS, Myles C, Pratt KJ, Washington JA. Cilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalis. Antimicrob Agents Chemother 1988; 32:1331-1335.
11. Pai MP, Jones AL, Mullen CK. Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method. Diagn Microbiol Infect Dis 2007; 58:129-132.
12. Denning DW, Stevens DA. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 1991; 35:1329-1333.
13. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001; 14:685-691.
14. Ramage G, VandeWalle K, Bachmann SP, et al. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002; 46:3634-3636.
15. Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 25 June 2007; E-pub ahead of print. doi: 10.1128/AAC.00676-07.
16. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004; 48:3407-3411.
17. Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother 2005; 49:5146-5148.
18. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandinspecific and Candida species-related differences. Antimicrob Agents Chemother 2007; 51:2257-2259. This study demonstrated species-related and echinocandin-specific differences for the paradoxical effect in Candida.
19. Stevens DA, McCullough MJ, Clemons KV, Martinez MC. Candida dubliniensis, a species with an extremely high frequency of paradoxical effect with caspofungin. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 27-30 September 2006. Abstract M-1756.
20. Gardiner RE, Souteropoulos P, Park S, Perlin DS. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol 2005; 43 (Suppl 1):S299-S305.
21. Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Eagle-like effect of caspofungin against Candida and Aspergillus spp.: association with homeostatic mechanisms of cell wall integrity. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 30 October-2 November 2004. Abstract M-1682.
22. Meletiadis J, Mouton JW, Meis JF, et al. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt 2, 3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001; 39:4256-4263.
23. Coen M, Bodkin J, Power D, et al. Antifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy. Antimicrob Agents Chemother 2006; 50:4018-4026.
24. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46:12-23.
25. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46:1857-1869.
26. Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42:2898-2905.
27. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44:3381-3388.
28. Van Vianen W, De Marie S, Ten Kate MT, et al. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. J Antimicrob Chemother 2006; 57:732-740.
29. Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006; 50:1293-1297.
30. Louie A, Deziel M, Liu W, et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49:5058-5068.
31. Stevens DA, White TC, Perlin DS, Selitrennikoff CP. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 2005; 51:173-178.
32. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006; 50:3160-3161. This study reported significant increases in cell wall chitin after exposure to high caspofungin concentrations.
33. Pfaller M, Riley J, Koerner T. Effects of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicans. Eur J Clin Microbiol Infect Dis 1989; 8:1067-1070.
34. Kraus PR, Fox DS, Cox GM, Heitman J. The Cryptococcus neoformans MAP kinase Mpk1 regulates cell integrity in response to antifungal drugs and loss of calcineurin function. Mol Microbiol 2003; 48:1377-1387.
35. Fox D, Smulian AG. Mitogen-activated protein kinase Mkp1 of Pneumocystis carinii complements the slt2Delta defect in the cell integrity pathway of Saccharomyces cerevisiae. Mol Microbiol 1999; 34:451-462.
36. Bussink HJ, Osmani SA. A mitogen-activated protein kinase (MPKA) is involved in polarized growth in the filamentous fungus, Aspergillus nidulans. FEMS Microbiol Lett 1999; 173:117-125.
37. Xue T, Nguyen CK, Romans A, May GS. A mitogen-activated protein kinase that senses nitrogen regulates conidial germination and growth in Aspergillus fumigatus. Eukaryot Cell 2004; 3:557-560.
38. Mizutani O, Nojima A, Yamamoto M, et al. Disordered cell integrity signaling caused by disruption of the kexB gene in Aspergillus oryzae. Eukaryot Cell 2004; 3:1036-1048.
39. Agarwal AK, Rogers PD, Baerson SR, et al. Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J Biol Chem 2003; 278:34998-35015.
40. Reinoso-Martin C, Schuller C, Schuetzer-Muehlbauer M, Kuchler K. The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling. Eukaryot Cell 2003; 2:1200-1210.
41. Munro CA, Selvaggini S, de Bruijn I, et al. The PKC,HOGand Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol Microbiol 2007; 63:1399-1413. This study demonstrated the coordination of chitin synthesis by the PKC cell wall integrity, high-osmolarity glycerol mitogen-activated protein kinase, and calcineurin pathways in C. albicans.
42. Wiederhold NP, Wickes BL, Patterson TP. Increased gene expression of mitogen-activated protein kinase A is associated with attenuated caspofungin activity in Aspergillus fumigatus. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 27-30 September 2006. Abstract M-364.
43. Klont RR, Mennink-Kersten MA, Ruegebrink D, et al. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis 2006; 43:e23-e25.
44. Maertens J, Glasmacher A, Selleslag D, et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005; 41:e9-e14.
45. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187:1834-1843.
46. Park S, Paderu P, Perlin DS. Human serum modulates the antifungal efficacy of echinocandin drugs. In: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 27-30 September 2006. Abstract M-307.
47. Lavediere M, Laonde RG, Bail JG, et al. Progressive loss of echinocandin activity following prolonged use for treatment of Cadida albicans oesophagitis. J Antimicrob Chemother 2006; 57:705-708.
48. Miller CD, Lomaestro BW, Park S, Perlin DS. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 2006; 26:877-880.
49. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49:3264-3273.